1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors

Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors

The present Competitive Intelligence Report about Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting Her2 for treatment of Her2 positive breast and gastric cancer as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

With the approval and launch of next generation Her2 antibodies Perjeta and Kadcyla, Roche has succeeded in boosting its Her2 franchise lead by Herceptin in 2013 to US$ 7.5 bln (+14% vs previous year).
The commercial attractiveness of trastuzumab has stimulated many companies to create and develop next generation anti-Her2 monoclonal antibodies (mabs) with improved properties compared with the humanized antibody trastuzumab. These biosuperior antibodies include antibody-drug conjugates, bi- and multispecific antibodies and engineered Her2 antibodies. The forthcoming patent expiry for Herceptin has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and launched in less regulated markets.
The report includes a compilation of currently active projects in development of Her2 targeting antibodies for treatment of Her2 positive breast and gastric cancer. In addition, the report lists company-specific R&D pipelines of Her2 antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors
Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors
Table of Contents
1. Trastuzumab Biosimilars and Biobetters/Biosuperiors

Marketed Her2 Antibodies

-           Herceptin Sales and Pipeline

-           Perjeta Sales and Pipeline

-           Kadcyla Sales and Pipeline

Trastuzumab Biobetters/Biosuperiors

-           Engineered Her2 Antibodies

-           Bi- and Multispecific Her2 Antibodies

-           Her2 Antibody-Drug Conjugates

-           Her2 Imaging Antibodies

Trastuzumab Biosimilars
2.  Corporate Her2 Antibody Biosimilar and Biobetter Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Monoclonal Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Monoclonal Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Monoclonal Antibody Therapeutics Market: Overview Monoclonal antibodies are a type of biological therapy used in the treatment serious conditions such as cancer, rheumatoid arthritis, Crohn’s ...

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. In this report, ...

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

  • $ 4995
  • Industry report
  • December 2016
  • by GBI Research

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments ...


Download Unlimited Documents from Trusted Public Sources

Insulin Market and Diabetes Statistics in the US

  • March 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Opioid Market in China

  • March 2017
    4 pages
  • Opioid  

  • China  

View report >

Eye Disease Statistics and Type 2 Diabetes Statistics in the US

  • March 2017
    13 pages
  • Eye Disease  

    Type 2 Diabetes  

  • United States  

    World  

View report >

Related Market Segments :

Monoclonal Antibody

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.